GCGR and metabolic dysfunction-associated steatotic liver disease: Studies suggest that a 30% reduction in LFC is correlated with >2-point reduction in NAFLD activity scores and a 50% LFC reduction is correlated with MASLD resolution (absence of ballooning with minimal to no lobular inflammation) and improved fibrosis.33,42 Studies show that survodutide and pemvidutide (dual GCGR/GLP-1RA) are more potent than GLP-1RA because of the appetite suppressing effects of GLP-1RA and the hepatic fat content reduction by GCGR agonism in hepatocyte to synergically enhance liver function and improve fibrosis.41,43